

**Centers for Disease Control and Prevention
Model Performance Evaluation Program**

Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Testing

**Figures Used to Summarize the
Participant Laboratory Results
for the November 2001 Shipment**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Public Health Practice Program Office
Division of Laboratory Systems
Atlanta, Georgia 30341-3717**



Use of trade names is for identification only and does not constitute endorsement by the U.S. Department of Health and Human Services.

Report of the November 2001 Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Performance Evaluation Sample Testing Results Provided by Participant Laboratories in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).

The production of this report was coordinated in CDC by:

Public Health Practice Program Office.....Edward L. Baker, M.D., M.P.H., Director
Division of Laboratory Systems.....Robert Martin, Dr.P.H., Director
.....Thomas L. Hearn, Ph.D., Deputy Director

The material in this report was developed and prepared by:

Model Performance Evaluation Program (MPEP).....G. David Cross, M.S., Chief (Acting)
HTLV Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8091.

**Centers for Disease Control and Prevention (CDC)
Model Performance Evaluation Program
Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Testing
November 2001 Participant Laboratory Shipment**

Table 1

Panel Letter	Vial Label	CDC Donor Number	CDC Contractor Result ²	Laboratory Interpretation ¹			
				INIT. ³	FINAL ⁴	WB	IIF
A	A1, A4	3	Positive, HTLV-I	—	—	—	—
	A2	1	Negative	—	—	—	—
	A3	2	Positive, HTLV-II	—	—	—	—
	A5, A6	4	Negative	—	—	—	—
B	B1, B6	4	Negative	—	—	—	—
	B2	1	Negative	—	—	—	—
	B3	2	Positive, HTLV-II	—	—	—	—
	B4, B5	3	Positive, HTLV-I	—	—	—	—


¹ Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory result with CDC result.

² The CDC result was obtained after composite EIA, WB, and RIPA testing, by CDC contractor, and employing the interpretation criteria of the Public Health Service Working Group.

³ Initial EIA interpretation

⁴ Final EIA interpretation

Figure 1. Frequency of HTLV-I/II antibody test result interpretations, by sample type (reactivity), for enzyme immunoassay (EIA), Western blot (WB), and indirect immunofluorescence (IIF), reported by participant laboratories for the November 2001 shipment



* = Indeterminate is not an EIA interpretation option; these areas have been left blank





Figure 2. Percentage of HTLV-I/II participant laboratories, by laboratory type, that reported EIA, WB, and IIF results to the CDC for the November 2001 shipment




Figure 3. Combination of HTLV-I/II antibody tests reported by participant laboratories for the November 2001 shipment




Figure 4. Types of HTLV-I/II antibody test kits used for enzyme immunoassay, Western blot, and indirect immunofluorescence, as reported by participant laboratories to the CDC for the November 2001 shipment










Figure 5. Enzyme immunoassay HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the November 2001 shipment



Test Result Interpretations

■ Non-Reactive ■ Reactive



Figure 6. Western blot HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the November 2001 shipment



Test Result Interpretations

Non-Reactive
 Indeterminate
 Reactive

Figure 7. Indirect immunofluorescence HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the November 2001 shipment



Test Result Interpretations

- Non-Reactive
- Indeterminate
- Reactive

Figure 8. Western blot HTLV-I/II antibody band patterns reported to CDC by participant laboratories for the November 2001 shipment




Figure 9. Fluorescence intensity patterns, of HTLV-I/II-infected cells, for IIF results reported to CDC by participant laboratories for the November 2001 shipment




Figure 10. Types of 'Other' HTLV antibody test kits used and results reported by participant laboratories to the CDC for the November 2001 shipment




Figure 11. HTLV-I/II antigen lines reported to CDC by participant laboratories using INNO-LIA for the November 2001 shipment

